

# **Monitoring of Clearance of Hepatitis C Virus-RNA In Therapeutic Treated Patients By Recent Molecular Techniques**

**A thesis**

Submitted for Partial Fulfillment of Master Degree  
Of Science in Microbiology (Medical Virology and Molecular Biology)

**By**

**Ahmed Khedr Mohamed Haredi**

B.Sc. Microbiology  
Ain Shams University

**Under Supervision of**

**Prof. Dr. Ahmed B. Barakat**

Professor of Virology,  
Microbiology Department,  
Faculty of Science.  
Ain Shams University

**Prof. Dr. Mohamed S. Salama**

Professor of Molecular biology,  
Faculty of Science,  
Ain Shams University

**Dr. Hossam El Din A. Ghanem**

Lecturer of Virology,  
Microbiology Department,  
Faculty of Science,  
Ain Shams University

**Department of Microbiology**

**Faculty of Science  
Ain Shams University**

**2009**

# استخدام طرق جزيئية حديثه فى تقييم مدى الكشف عن فيروس الالتهاب الكبدي الوبائي "سى" فى المرضى الخاضعين للعلاج دوائياً

كجزء متمم للحصول على درجه الماجستير  
فى الميكروبيولوجى  
(تخصص علم الفيروسات والبيولوجيا الجزيئية)

رساله مقدمه من  
أحمد خضر محمد هريدى  
بكالوريوس العلوم- قسم الميكروبيولوجى  
جامعه عين شمس

تحت إشراف

أ.د. محمد سيد سلامه  
أستاذ البيولوجيه الجزيئيه،  
كلية العلوم،  
جامعه عين شمس

أ.د. أحمد بركات بركات  
أستاذ الفيروسولوجى،  
قسم الميكروبيولوجى،  
كلية العلوم،  
جامعه عين شمس

د. حسام الدين أحمد غانم  
مدرس الفيروسولوجى،  
قسم الميكروبيولوجى،  
كلية العلوم،  
جامعه عين شمس

قسم الميكروبيولوجى – كلية العلوم  
جامعة عين شمس

2009

# Contents

	Page
List of abbreviations	III
List of figures	VII
List of Tables	X
<i>Chapter one</i> : Introduction	1
<i>Chapter Two</i> : Review of Literature	4
1.   ▶ Discovery of Hepatitis C Virus (HCV)	4
2.   ▶ Molecular virology of HCV	5
3.   ▶ Epidemiology of hepatitis C virus infection	13
4.   ▶ Immuno-pathogenesis of HCV	20
5.   ▶ Natural history and clinical manifestations	23
6.   ▶ Diagnosis of Hepatitis C virus infection	25
7.   ▶ Treatment of HCV	35
<i>Chapter Three</i> : Materials and Methods	45
3.1. ▶ Qualitative determination of antibodies to hepatitis C virus (anti-HCV) in human serum samples	45
3.2. ▶ HCV-RNA Quantitative by branched DNA (b-DNA) technology	51
3.3. ▶ HCV-RNA qualitative assay by Transcription mediated amplification technology (TMA)	58

3.4.	▶ HCV Genotyping Assay	67
3.5.	▶ Quantitative determination of Alanine aminotransferase (ALT) liver biomarker	76
3.6.	▶ Statistical analysis of collected data	78
<i>Chapter Four</i>	: Results	81
<i>Chapter Five</i>	: Discussion	142
<i>Chapter Six</i>	: 6.1.▶ Summary	157
	: 6.2.▶ Conclusion and recommendations	161
<i>Chapter Seven</i>	: References	164
•	Appendixes	i
•	Arabic Summary	1

## **Acknowledgement**

I would like to express my thanks and gratitude to ***Professor Dr. Ahmed B. Barakat*** Professor of Virology, Microbiology Department, Faculty of Science, Ain Shams University, for his kind supervision, guidance and encouragement. His continuous help and endless support are greatly appreciated for suggesting the point of this thesis, building up the hypothesis related to the results. Also, I thank him for his continues support and valuable guidance in all of the theoretical and practical aspects of this work. I am very lucky to have great opportunity to be of his students from undergraduate studies until now.

My deepest heartfelt gratefulness is due to ***Professor Dr. Mohamed S. Salama*** Professor of Molecular biology, Faculty of Science, and Vice President of Ain Shams University for Postgraduate Studies and Research, for his kind supervision, guidance, encouragement, continuous help and endless support. It was of my best luck to be a member of his students from undergraduate studies until now, also deep thanks for his teaching us how to take a decision not only in the scientific work but also in our life as a whole.

I am also very grateful to ***Dr. Hossam El Din A. Ghanem*** lecturer of Virology, Microbiology Department, Faculty of Science Ain Shams University, for his kind supervision and continuous encouragement. I also thank him for his endless support and continuous effort in all stages in the work.

Sincere thanks and gratitude is to ***Prof. Dr. Momena Abdel Wahab Kamel*** the Head Manger of Al Mokhtabar Laboratories company and also endless deep thanks are to ***Prof. Dr. Hind El-Sherbiny***, the Vice Head Manger of Al Mokhtabar Laboratories company. Many endless thanks to ***Dr. Seham Ibrahim*** the general manager of Al Mokhtabar laboratories branches and research, for her

kindly agreement to carry out my work at Al Mokhtabar laboratories and for her scientific and medical help.

Many thanks and gratitude to ***Dr. Sameh Refaat El sayed*** the general manager of Delta area, Al Mokhtabar Laboratories and team member of Banha blood bank, for his kindly help. Thanks and gratitude is to all team work at Al Mokhtabar laboratories in Egypt

Many thanks to ***Dr. Khalid Atef Abdel Aziz*** team member of biomedical technology Department, National Research Center, in Cairo, for his thoughtful help and his continuous Scientific supports specially in molecular work in the study, also I thank ***Ashraf Hamid*** laboratory technician, Sayed Galal Hosbital, Al Azhar university, for his kind help and effort.

Many thanks to ***Dr. BashirAhmed Mohammed Al-Oferiri Staff*** member of IBB University, for his kind help, and effort and time.

Finally I thank ***Statisticist: Abdel Aziz M Elgarf*** for his help in scientific basis of statistical analysis in the study.

## **List of Abbreviations**

<b>ALT</b>	: Alanine aminotransferase
<b>APC</b>	: Antigen presenting cells
<b>AP</b>	: Alkaline phosphatase
<b>b-DNA</b>	: Branched DNA
<b>BSA</b>	: Bovine serum albumin
<b>CAM</b>	: Complementary and alternative medicine
<b>CD 81</b>	: Cluster of differentiation
<b>CDC</b>	: Centers for Disease Control and Prevention
<b>cDNA</b>	: Complementary DNA
<b>CTL</b>	: Cytotoxic T lymphocytes
<b>DDB</b>	: Dimethyl dimethoxy brphenyl Dicarboxylate
<b>DMS</b>	: Data Management Software
<b>dNTPs</b>	: Deoxy nucleotide triphosphates
<b>E1</b>	: Envelope protein 1
<b>E2</b>	: Envelope protein 2
<b>ELISA</b>	: Enzyme-Linked Immunosorbent Assay
<b>ER</b>	: Endoplasmic reticulum
<b>ETR</b>	: End of treatment response

<b>EVR</b>	: Early viral response
<b>FDA</b>	: Food and drug administration
<b>HBV</b>	: Hepatitis B virus
<b>HEPES</b>	: N-2Hydroxyethylpiperazine-2N- ethanesulfonic acid
<b>HCC</b>	: Hepatocellular carcinoma
<b>HCV</b>	: Hepatitis C Virus
<b>HIV</b>	: Human immunodeficiency virus
<b>HPA</b>	: Hybridization Protection Assay
<b>HRP</b>	: Horseradish peroxidase
<b>IFN- <math>\alpha</math></b>	: Interferon alpha
<b>IRES</b>	: Internal ribosome entry site
<b>ISG</b>	: Interferon-stimulated gene
<b>ISGF3</b>	: Interferon-stimulated gene factor 3
<b>ISDR</b>	: Interferon-sensitivity–determining region
<b>ISRES</b>	: Interferon-stimulated response elements
<b>IRF9</b>	: Interferon regulatory factor 9
<b>IU/ml</b>	: International unit per milliliter
<b>Kb</b>	: Kilo bases
<b>LDL</b>	: Low-density lipoprotein
<b>LIA</b>	: Line immunoassay



<b>LiPA</b>	: Line probe assay
<b>MES</b>	: N-Morpholino ethane sulfonic acid
<b>MHC</b>	: Major histocompatibility complex
<b>MU</b>	: Million units
<b>NADH</b>	: Nicotinamide Adenine Dinucleotide-Hydrogen
<b>NaTHNaC</b>	: National travel health network and centre
<b>NATs</b>	: Nucleic acid tests
<b>NCR</b>	: Non coding regions
<b>NIH</b>	: National Institutes of Health
<b>NTPs</b>	: Nucleotide triphosphates
<b>NK</b>	: Natural killer cell
<b>NS</b>	: Non structure proteins
<b>ORF</b>	: Open reading frame
<b>PBMCs</b>	: Peripheral blood mononuclear cells
<b>PBS:</b>	: Phosphate buffer saline
<b>PCR</b>	: Polymerase chain reaction
<b>PEG-interferon</b>	: Pyglated interferon
<b>PKR</b>	: Double stranded RNA dependant protein kinase R
<b>QS</b>	: Quantitation standard
<b>RBV</b>	: Ribavirin
<b>RdRp</b>	: RNA-dependent RNA polymerase

<b>RNA</b>	: Ribonucleic acid
<b>RT-PCR</b>	: Reverse transcription polymerase chain reaction
<b>RTU</b>	: Relative light unit
<b>RVR</b>	: Rapid virological response
<b>SPSS</b>	: Statistical package for social sciences
<b>STAT</b>	: Signal transducers and activators of transcription
<b>SVR</b>	: Sustained virological response
<b>TMA</b>	: Transcription mediated amplification
<b>TMB</b>	: Tetramethylbenzidine
<b>TNF-<math>\alpha</math></b>	: Tumor necrosis factor- $\alpha$
<b>TTU</b>	: Ten tube unit
<b>UTR</b>	: Untranslated region
<b>HVR</b>	: Hypervariable region
<b>WHO</b>	: World health organization

## **List of figures**

	<b>Page</b>
<b><i>Fig. (a) : Diagrammatic structure of HCV genome</i></b>	<b>7</b>
<b><i>Fig. (b) : Schematic diagram of the HCV life cycle</i></b>	<b>12</b>
<b><i>Fig. (c) : HCV epidemiology throughout the world, showing the high incidence in Egypt compared to other countries</i></b>	<b>14</b>
<b><i>Fig. (d) : Proposed mechanism of interferon alpha action against HCV</i></b>	<b>38</b>
<b><i>Fig. (E) : Diagram of the target capture specimen processing method for the Gen-Probe TMA assays</i></b>	<b>59</b>
<b><i>Fig. (F) : Diagrammatic representation of the hybridization procedure and the color development</i></b>	<b>68</b>
<b><i>Fig. (G) : INNO-LiPA pattern obtained with the Versant HCV Genotyping assay</i></b>	<b>69</b>
<b><i>Fig. 1 : The prevalence of HCV-Ab in 403 random individuals</i></b>	<b>81</b>
<b><i>Fig. 2 : The percent of viral Self clearers (Category one) with contrast to patients of persistence viremias (Category two)</i></b>	<b>84</b>
<b><i>Fig. 3 : Diagrammatic representation of different patients' response behaviors to PEG-interferon <math>\alpha</math> 2a / RBV therapy</i></b>	<b>102</b>

<b>Fig. 4</b>	<b>: Diagrammatic representation of different sustained responses or non responses of patients to PEG-interferon <math>\alpha</math> 2a / RBV therapy with respect to different HCV subtypes</b>	<b>105</b>
<b>Fig. 5</b>	<b>: Diagrammatic representation of relation between sustained response or non response of patients to PEG-interferon <math>\alpha</math> 2a /RBV therapy and HCV-RNA quantitative b-DNA results at week 4</b>	<b>108</b>
<b>Fig. 6</b>	<b>: Diagrammatic representation of relation between sustained response or non response of patients to PEG-interferon <math>\alpha</math> 2a / RBV therapy and b-DNA results at week 12</b>	<b>111</b>
<b>Fig. 7</b>	<b>: Diagrammatic representation between sustained response or non response of patients to PEG-interferon <math>\alpha</math> 2a /RBV therapy and mean of baseline viral load in all examined patients</b>	<b>113</b>
<b>Fig. 8</b>	<b>: Diagrammatic representation of cutoff viral load with respect to sustained response or non response of patients to therapy (Cutoff <math>\leq</math> 416712 IU/ml)</b>	<b>117</b>
<b>Fig. 9</b>	<b>: Diagrammatic correlation between detection of HCV-RNA by TMA at week 24 results and sustained response or non response of patients to PEG-interferon <math>\alpha</math> 2a / RBV therapy</b>	<b>120</b>
<b>Fig. 10</b>	<b>: Diagrammatic correlation between detection of HCV-RNA by TMA at week 48 results</b>	<b>123</b>

and sustained response or non response of patients to PEG-interferon  $\alpha$  2a /RBV therapy

- Fig. 11* : Diagrammatic correlation between HCV- RNA by TMA at week 72 results and sustained response or non response of patients to PEG-interferon  $\alpha$  2a /RBV therapy 125**
- Fig. 12* : The comparison between biochemical response and non response of patients to PEG- interferon  $\alpha$  2a / RBV therapy (line) 132**
- Fig. 13* : The comparison between sustained biochemical response and non response of patients to PEG-interferon RBV treated patients (Histogram) 134**
- Fig. 14* : Diagrammatic representation of correlation between mean ALT values and HCV-RNA detection by TMA 138**

## **List of Tables**

	<b>Page</b>
<b><i>Table (a)</i> : First round PCR thermal profile as HCV first profile.</b>	<b>73</b>
<b><i>Table (b)</i> : Second round PCR thermal profile as HCV second profile</b>	<b>74</b>
<b><i>Table 1</i> : HCV-RNA viral load obtained by b-DNA with TMA confirmation in patients of Category one</b>	<b>83</b>
<b><i>Table 2</i> : Baseline viral load of HCV-RNA by b-DNA technique in patients of Category two</b>	<b>87</b>
<b><i>Table 3</i> : Detection of HCV Genotype (s) in Category two patients by INNO LiPA technique</b>	<b>88</b>
<b><i>Table 4</i> : Viral load of HCV-RNA by b-DNA technique at week 4 from therapy</b>	<b>89</b>
<b><i>Table 5</i> : Viral load of HCV-RNA by b-DNA technique at week 12 from therapy</b>	<b>91</b>
<b><i>Table 6</i> : Detection of HCV-RNA in patients of Subgroup (A1) at week 24 of treatment</b>	<b>93</b>
<b><i>Table 7</i> : Detection of HCV-RNA in patients of Subgroup (A2) at week 24 of treatment</b>	<b>95</b>
<b><i>Table 8</i> : Viral load of HCV in patients of group (B) at week 24 from therapy</b>	<b>96</b>
<b><i>Table 9</i> : Detection of HCV-RNA at week 48 of therapy (End of treatment)</b>	<b>98</b>

<b>Table 10</b>	<b>: Detection of HCV-RNA at week 72 from therapy (Sustained virological response)</b>	<b>100</b>
<b>Table 11</b>	<b>: Response of patients to PEG- interferon <math>\alpha</math> 2a / RBV Therapy at different intervals of therapeutic treatment</b>	<b>101</b>
<b>Table 12</b>	<b>: The sustained response or non response of patients to PEG-interferon <math>\alpha</math> 2a / RBV therapy with respect to different HCV subtypes</b>	<b>104</b>
<b>Table 13</b>	<b>: The correlation between sustained responder or non responder patients to PEG-interferon <math>\alpha</math> 2a /RBV therapy and HCV-RNA quantitative value applied by b-DNA results at 4 weeks of treatment</b>	<b>107</b>
<b>Table 14</b>	<b>: The correlation between sustained responder or non responder patients to PEG-interferon <math>\alpha</math> 2a /RBV therapy and HCV-RNA quantitative value applied by b-DNA results at 12 weeks of treatment</b>	<b>110</b>
<b>Table 15</b>	<b>: Correlation between baseline mean viral load and sustained response or non response of patients to PEG-interferon <math>\alpha</math> 2a / RBV therapy</b>	<b>112</b>
<b>Table 16</b>	<b>: The correlation between sustained responder and non responder patients to PEG-interferon <math>\alpha</math> 2a /RBV therapy and HCV-RNA quantitative value applied by b-DNA results at baseline (zero time of treatment)</b>	<b>115</b>